{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:45Z","timestamp":1792789005060,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1.8.029.25 N"],"award-info":[{"award-number":["1.8.029.25 N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.autrev.2024.103589","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T12:42:22Z","timestamp":1722948142000},"page":"103589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms"],"prefix":"10.1016","volume":"23","author":[{"given":"Elvis","family":"Hysa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Gotelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Campitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Teresa","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Amedeo","family":"Cimmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103589_bb0005","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","article-title":"Polymyalgia rheumatica","volume":"402","author":"Esp\u00edgol-Frigol\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103589_bb0010","article-title":"Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases?","volume":"103415","author":"Salvarani","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2024.103589_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard-2023-224768","article-title":"Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica","volume":"83","author":"De Miguel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105558","article-title":"Clinical phenotype and complications of large vessel giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Lyne","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2024.103589_bb0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","article-title":"Disease stratification in GCA and PMR: state of the art and future perspectives","volume":"19","author":"Tomelleri","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103589_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103589_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/kead471","article-title":"Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review","volume":"63","author":"Hysa","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103589_bb0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.autrev.2024.103589_bb0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert perspective: immune checkpoint inhibitors and rheumatologic complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European league against rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0055","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2024.103589_bb0060","doi-asserted-by":"crossref","unstructured":"R\u00e9gnier P., Le Joncour A., Maciejewski-Duval A., Darrasse-J\u00e8ze G., Dolladille C., Meijers W.C., et al. CTLA-4 pathway is instrumental in Giant cell arteritis. Circ Res 2023 Aug 4;133(4):298-312.","DOI":"10.1161\/CIRCRESAHA.122.322330"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2024.103589_bb0065","article-title":"Immune checkpoint inhibitors-induced large vessel Vasculitis: data from a multicenter study [abstract]","volume":"75","author":"Cottu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0070","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.autrev.2024.103589_bb0075","article-title":"Identification and classification of polymyalgia Rheumatica (PMR) and PMR-like syndromes following immune checkpoint inhibitors (ICIs) therapy: discussion points and Grey areas emerging from a systematic review of published literature","volume":"7","author":"Manzo","year":"2020","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.autrev.2024.103589_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.rdc.2024.02.001","article-title":"Immune checkpoint inhibitor-induced polymyalgia Rheumatica","volume":"50","author":"Liew","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2024.103589_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2024.103589_bb0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.autrev.2024.103589_bb0095","doi-asserted-by":"crossref","unstructured":"Vermeulen O.C.B., Brouwer E., Slart R., Sandovici M., Rutgers A., Hilterman T.J., et al. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology (Oxford) 2024 Feb 9:keae099. doi: 10.1093\/rheumatology\/keae099. Online ahead of print.","DOI":"10.1093\/rheumatology\/keae099"},{"issue":"3","key":"10.1016\/j.autrev.2024.103589_bb0100","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica\u2013like syndrome after immune checkpoint inhibitor therapy","volume":"81","author":"Fremont","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-Centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-Centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2024.103589_bb0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2024.103589_bb0125","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103589_bb0135","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/life13040877","article-title":"Rheumatic diseases development in patients treated by anti-PD1 immune checkpoint inhibitors: a single-Centre descriptive study","volume":"13","author":"Ceccarelli","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.autrev.2024.103589_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103589_bb0145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti\u2013programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2024.103589_bb0150","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.autrev.2024.103589_bb0155","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0160","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1078155220921543","article-title":"Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab","volume":"27","author":"Kethireddy","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.autrev.2024.103589_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103589_bb0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/ard.28.4.431","article-title":"Age-related rheumatoid factors. Incidence and characteristics","volume":"28","author":"Dequeker","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0180","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.60.11.1021","article-title":"Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study","volume":"60","author":"Caporali","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5114\/reum.2021.110600","article-title":"Feasibility and usefulness of a fast-track clinic for patients suspected of polymyalgia rheumatica: notes for a work schedule through a narrative review of published literature","volume":"59","author":"Hysa","year":"2021","journal-title":"Reumatologia"},{"issue":"3","key":"10.1016\/j.autrev.2024.103589_bb0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/ard-2023-225192","article-title":"Polymyalgia rheumatica: crafting the future of a simple (but not easy!) clinical syndrome","volume":"83","author":"Bond","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0200","article-title":"Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"van der Geest","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1684\/ejd.2016.2837","article-title":"Polymyalgia rheumatica occurring during treatment with ipilimumab","volume":"26","author":"Maniu","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejca.2018.07.318","article-title":"A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica","volume":"103","author":"Robilliard","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2024.103589_bb0215","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"Fuente","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103589_bb0220","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.autrev.2024.103589_bb0225","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1136\/annrheumdis-2020-218276","article-title":"Management of immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"Geest","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152110","article-title":"Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: a scoping review by the OMERACT irAE working group","volume":"58","author":"Ghosh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0235","first-page":"S555","article-title":"Immune checkpoint inhibitor-associated polymyalgia Rheumatica\/Giant cell arteritis occurring in a patient after treatment with Nivolumab","volume":"27","author":"Betrains","year":"2021","journal-title":"J"},{"key":"10.1016\/j.autrev.2024.103589_bb0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bcr-2021-246443","article-title":"Giant cell arteritis associated with PD-1 inhibition","volume":"14","author":"Couette","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2024.103589_bb0245","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/art.42325","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for Giant cell arteritis","volume":"74","author":"Ponte","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103413","article-title":"Performance of the new 2022 ACR\/EULAR classification criteria for giant cell arteritis in clinical practice in relation to its clinical phenotypes","volume":"22","author":"Narv\u00e1ez","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0255","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0260","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103355","article-title":"Diagnostic yield of combined cranial and large vessel PET\/CT, ultrasound and MRI in giant cell arteritis: a systematic review and meta-analysis","volume":"22","author":"Moreel","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0270","article-title":"A rare case of Giant cell arteritis after the Administration of Checkpoint Inhibitor Therapy in a metastatic renal cell carcinoma patient","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2024.103589_bb0275","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2024.103589_bb0280","article-title":"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma","volume":"20","author":"Narala","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.autrev.2024.103589_bb0285","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103589_bb0290","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2024.103589_bb0295","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3892\/etm.2023.12242","article-title":"Polymyalgia rheumatica: an update (review)","volume":"26","author":"Florescu","year":"2023","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.autrev.2024.103589_bb0300","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41584-020-0503-4","article-title":"Sex steroids and autoimmune rheumatic diseases: state of the art","volume":"16","author":"Cutolo","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0305","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European league against rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: the impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0315","doi-asserted-by":"crossref","first-page":"1024112","DOI":"10.3389\/fimmu.2022.1024112","article-title":"Sex - a potential factor affecting immune checkpoint inhibitor therapy for cancers","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103589_bb0320","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.autrev.2024.103589_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2024.103589_bb0330","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard-2023-223895","article-title":"Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients","volume":"82","author":"Monti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0335","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","article-title":"Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study","volume":"41","author":"Salvarani","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0340","doi-asserted-by":"crossref","first-page":"441","DOI":"10.55563\/clinexprheumatol\/s4c5k3","article-title":"Polymyalgia rheumatica without elevated baseline acute phase reactants","volume":"39","author":"Manzo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0345","doi-asserted-by":"crossref","first-page":"32","DOI":"10.55563\/clinexprheumatol\/gdps1r","article-title":"Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?","volume":"39","author":"Marsman","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0350","doi-asserted-by":"crossref","first-page":"e19514","DOI":"10.1200\/jco.2013.31.15_suppl.e19514","article-title":"Prevalence of autoimmune conditions in patients with Waldenstrom macroglobulinemia: exploratory analysis of a series of consecutive patients","volume":"31","author":"Atienza","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2024.103589_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100115","article-title":"Polymyalgia rheumatica: a case series from Colombia and analysis of Latin America","volume":"4","author":"Toro-Gutierrez","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2024.103589_bb0360","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40744-021-00299-8","article-title":"Inflammatory markers are quickly improved by tocilizumab in early polymyalgia Rheumatica and might predict early response to Interleukin-6 blockade","volume":"8","author":"Carvajal","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2024.103589_bb0365","doi-asserted-by":"crossref","first-page":"102995","DOI":"10.1016\/j.autrev.2021.102995","article-title":"Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review","volume":"21","author":"Hysa","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0380","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-018-1757-y","article-title":"Comorbidities in polymyalgia rheumatica: a systematic review","volume":"20","author":"Partington","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103589_bb0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.1978.tb02202.x","article-title":"Autoimmune thyroid disease and the polymyalgia rheumatica-giant cell arteritis syndrome","volume":"9","author":"Dent","year":"1978","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.autrev.2024.103589_bb0390","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3899\/jrheum.160249","article-title":"Rate of comorbidities in Giant cell arteritis: a population-based study","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0395","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2022-eular.4396","article-title":"OP0015 proinflammatory monocytes and macrophages in synovial fluid and bursal tissue of patients with polymyalgia rheumatica: potent producers of IL-6 and gm-CSF","volume":"81","author":"Jiemy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0400","first-page":"174","article-title":"Gastrointestinal disorders as immune-related adverse events","volume":"2","author":"Balducci","year":"2021","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.autrev.2024.103589_bb0405","doi-asserted-by":"crossref","first-page":"1122430","DOI":"10.3389\/fimmu.2023.1122430","article-title":"Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations","volume":"14","author":"Williams","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103589_bb0410","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3747\/co.25.4235","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a brief review","volume":"25","author":"Myers","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.autrev.2024.103589_bb0415","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00296-009-0949-9","article-title":"Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica","volume":"30","author":"Dejaco","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103589_bb0420","article-title":"Innate and adaptive immunity in Giant cell arteritis","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103589_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103124","article-title":"Single-cell transcriptomic profiling reveals a pathogenic role of cytotoxic CD4+ T cells in giant cell arteritis","volume":"142","author":"Carmona","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103589_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000426","article-title":"Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study","volume":"3","author":"Cutolo","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103589_bb0435","first-page":"S9","article-title":"Epidemiology of polymyalgia rheumatica","volume":"18","author":"Cimmino","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0440","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12891-016-1127-3","article-title":"The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population","volume":"17","author":"Yates","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2024.103589_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102692","article-title":"Impact of age at diagnosis in polymyalgia rheumatica: a retrospective cohort study of 218 patients","volume":"19","author":"Van Hemelen","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0450","first-page":"321","article-title":"Sex differences in temporal arteritis and polymyalgia rheumatica","volume":"29","author":"Narvaez","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0455","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/ar293","article-title":"Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica","volume":"3","author":"Gonzalez-Gay","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1016\/j.autrev.2024.103589_bb0460","first-page":"S22","article-title":"Giant cell arteritis and polymyalgia rheumatica: role of viral infections","volume":"18","author":"Duhaut","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0465","doi-asserted-by":"crossref","first-page":"564","DOI":"10.55563\/clinexprheumatol\/vn1qbp","article-title":"Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single Centre","volume":"39","author":"Sobrero","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0470","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.semarthrit.2020.05.023","article-title":"A seasonal pattern in the onset of polymyalgia rheumatica and giant cell arteritis? A systematic review and meta-analysis","volume":"50","author":"Hysa","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0475","first-page":"655","article-title":"Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease","volume":"18","author":"Cutolo","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0480","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.rhu.0000231381.21179.e6","article-title":"Peripheral musculoskeletal manifestations in polymyalgia rheumatica","volume":"12","author":"Ceccato","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0485","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/35.11.1161","article-title":"A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis","volume":"35","author":"Myklebust","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0490","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","article-title":"Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study","volume":"30","author":"Cantini","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/reum.2018.74740","article-title":"Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis: a four-point guidance","volume":"56","author":"Manzo","year":"2018","journal-title":"Reumatologia"},{"key":"10.1016\/j.autrev.2024.103589_bb0500","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0505","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-021-02450-w","article-title":"A meta-analysis of the epidemiology of giant cell arteritis across time and space","volume":"23","author":"Li","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103589_bb0510","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","article-title":"Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study","volume":"77","author":"Partington","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0515","first-page":"S70","article-title":"Gender differences in giant cell arteritis: a case-control study","volume":"34","author":"Sturm","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103589_bb0520","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2022-222156","article-title":"Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids","volume":"81","author":"Estupi\u00f1\u00e1n-Moreno","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/jcm10010063","article-title":"Is there an association between herpetic infections and Giant cell arteritis? A population-based study","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2024.103589_bb0530","doi-asserted-by":"crossref","unstructured":"Bond M., Tomelleri A., Reatini M.A., Campochiaro C., Cattani G., Dagna L., et al. Impact of exposure to environmental particulate matter on the onset of giant cell arteritis. Arthritis Care Res (Hoboken) 2024 Jul 16. doi: 10.1002\/acr.25404. Online ahead of print.","DOI":"10.1002\/acr.25404"},{"key":"10.1016\/j.autrev.2024.103589_bb0535","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","article-title":"Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2024.103589_bb0540","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","article-title":"Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis","volume":"72","author":"Kermani","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0545","first-page":"10","article-title":"Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years","author":"Elfishawi","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103589_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152069","article-title":"Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica \u2013 a systematic review and meta-analysis","volume":"56","author":"Nielsen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103589_bb0555","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","volume":"84","author":"Garel","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2024.103589_bb0560","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2024.103589_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103589_bb0570","article-title":"Clinical patterns and follow-up of inflammatory arthritis and other immune-related adverse events induced by checkpoint inhibitors. A multicenter study","volume":"9","author":"G\u00f3mez-Puerta","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2024.103589_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803706","article-title":"Frequency of immune checkpoint inhibitor-induced Vasculitides: an observational study using data from the Japanese adverse drug event report database","volume":"13","author":"Kato","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2024.103589_bb0580","article-title":"Management of immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"van der Geest","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0585","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CJI.0000000000000163","article-title":"Nivolumab Causing a Polymyalgia Rheumatica in a Patient With a Squamous Non\u2013Small Cell Lung Cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2024.103589_bb0590","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-017-2410-x","article-title":"Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment","volume":"143","author":"Nakamagoe","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.autrev.2024.103589_bb0595","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1248\/yakushi.18-00161","article-title":"Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment","volume":"139","author":"Imai","year":"2019","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.autrev.2024.103589_bb0600","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/1078155218800386","article-title":"Polymyalgia rheumatica due to pembrolizumab therapy","volume":"25","author":"Iskandar","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.autrev.2024.103589_bb0605","doi-asserted-by":"crossref","first-page":"421","DOI":"10.21037\/tlcr.2020.03.01","article-title":"IgA vasculitis and polymyalgia rheumatica induced by durvalumab","volume":"9","author":"Casafont-Sol\u00e9","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.autrev.2024.103589_bb0610","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4081\/reumatismo.2020.1297","article-title":"Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab","volume":"72","author":"Perrotta","year":"2020","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2024.103589_bb0615","article-title":"Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab","volume":"3","author":"Lobo","year":"2020","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.autrev.2024.103589_bb0620","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjms.2021.04.010","article-title":"Nivolumab-induced polymyalgia Rheumatica in a patient with lung adenocarcinoma","volume":"362","author":"Kita","year":"2021","journal-title":"Am J Med Sci"},{"issue":"11","key":"10.1016\/j.autrev.2024.103589_bb0625","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217605","article-title":"Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor","volume":"81","author":"Moura","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103589_bb0630","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1093\/oncolo\/oyac026","article-title":"Joint-predominant rheumatic complications of immune checkpoint inhibitor therapy in patients with Thymic epithelial tumors","volume":"27","author":"Mullenix","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.autrev.2024.103589_bb0635","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.medcli.2023.04.030","article-title":"Polimialgia reum\u00e1tica tras tratamiento con pembrolizumab","volume":"161","author":"Ramirez-Poza","year":"2023","journal-title":"Med Clin"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T10:21:15Z","timestamp":1725790875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":127,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1568997224000806"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103589","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103589"}}